Indian Immunologicals Ltd, a subsidiary of the National Dairy Development Board (NDDB), was established in 1982 to make vaccines, including rabies, more affordable in the country. Over the past 25 years, it has sold a total of 210 million doses.
The company provides around seven to eight million vaccines to governments, with about four million doses sold domestically and another five to six million exported.
IIL faced controversy in 2025 after Australian health authorities issued a warning about counterfeit versions of the Abhayrab rabies vaccine in India. The company responded that it was an isolated case from January involving just one batch of about 80,000 vials. They also stated that every vaccine batch produced in India is tested and approved by the Central Drugs Laboratory before being sold or administered.